MedTrace Logo

Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo.

NCT06352541 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2026-04-16

No results posted yet for this study

Summary

This is a phase I study evaluating safety and tolerability through the incidence of unexpected adverse events and IOP measurement, as well as through the incidence of stinging after its administration, compared to placebo.

Conditions

  • Healthy

Interventions

DRUG

PRO-232

Moxifloxacin 0.5% and Dexamethasone Phosphate 0.1%

OTHER

Placebo

Vehicle Control, ophthalmic solution

Sponsors & Collaborators

  • Laboratorios Sophia S.A de C.V.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-02-08
Primary Completion
2024-05-28
Completion
2024-05-28

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06352541 on ClinicalTrials.gov